STAT’s Post

Stay cool with the latest edition of "Weekly Update!" We have not one but two STAT investigations - plus, biotech updates, Fauci on the First Opinion podcast, Elmo and friends, and much more! Read now ⬇

CTE can only be diagnosed after death. But Ann McKee and her colleagues published new research this year that could eventually help identify the condition while people are still alive. She spoke to STAT in a new Q/A. https://trib.al/HZi08Eo

Nominations for the 2024 #STATWunderkinds close tomorrow! Last call to make a submission: https://trib.al/S7F6AMi

Medicare regulators proposed new codes that support payment for digital mental health treatments. https://trib.al/kycqy5h

Cancer studies fail all the time. But it’s far less common, and quite alarming, to see a study in which the experimental drug showed “reduced efficacy” (Roche’s terminology) in relation to a comparator, Adam Feuerstein writes. Simply stated: The patients fared meaningfully worse. Read more in Adam’s Biotech Scorecard. https://trib.al/J4lnm0l

Pfizer plans to advance a new, once-a-day formulation of its experimental obesity drug danuglipron, meant to be a pill version in the same class as Wegovy and Zepbound. https://trib.al/JzUXv7i

The FDA rejected Novo Nordisk’s weekly insulin for the treatment of diabetes. https://trib.al/fJZb1j8

The Federal Trade Commission plans to sue the three largest PBMs. Here's why: https://trib.al/psBpzZC

The federal government will not modify regulations that dictate how hospitals publish their prices for consumers. https://trib.al/dWyrGEG

Fourth time’s the charm? Sanford Health hopes to shake off a run of failed deals by snapping up a $3 billion Wisconsin health system. https://trib.al/33w87Qi